Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

[Expert Workshop COPD: Lungs and Heart - Quite Often Ill Together].

Jany B, Bals R, Dreher M, Held M, Jany L, Rembert Koczulla A, Pfeifer M, Randerath W, Watz H, Wilkens H, Steinkamp G.

Pneumologie. 2019 Sep 9. doi: 10.1055/a-0914-9566. [Epub ahead of print] German.

PMID:
31499562
2.

Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression.

Andreas S, Röver C, Heinz J, Straube S, Watz H, Friede T.

Respir Res. 2019 Aug 16;20(1):186. doi: 10.1186/s12931-019-1163-2.

3.

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.

Singh D, Beeh KM, Colgan B, Kornmann O, Leaker B, Watz H, Lucci G, Geraci S, Emirova A, Govoni M, Nandeuil MA.

Respir Res. 2019 Aug 9;20(1):180. doi: 10.1186/s12931-019-1142-7.

4.

Consequences of chronic kidney disease in chronic obstructive pulmonary disease.

Trudzinski FC, Alqudrah M, Omlor A, Zewinger S, Fliser D, Speer T, Seiler F, Biertz F, Koch A, Vogelmeier C, Welte T, Watz H, Waschki B, Fähndrich S, Jörres R, Bals R; German COSYCONET consortium.

Respir Res. 2019 Jul 12;20(1):151. doi: 10.1186/s12931-019-1107-x.

5.

Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort.

Trudzinski FC, Kahnert K, Vogelmeier CF, Alter P, Seiler F, Fähndrich S, Watz H, Welte T, Speer T, Zewinger S, Biertz F, Kauczor HU, Jörres RA, Bals R; COSYCONET consortium.

Respir Med. 2019 Jul - Aug;154:18-26. doi: 10.1016/j.rmed.2019.06.007. Epub 2019 Jun 11.

PMID:
31203096
6.

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.

Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E.

Int J Chron Obstruct Pulmon Dis. 2019 Mar 22;14:667-682. doi: 10.2147/COPD.S189138. eCollection 2019.

7.

Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial.

Watz H, Nagelschmitz J, Kirsten A, Pedersen F, van der Mey D, Schwers S, Bandel TJ, Rabe KF.

Pulm Pharmacol Ther. 2019 Jun;56:86-93. doi: 10.1016/j.pupt.2019.03.009. Epub 2019 Mar 24.

PMID:
30917927
8.

Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD.

Alter P, Watz H, Kahnert K, Rabe KF, Biertz F, Fischer R, Jung P, Graf J, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2019 Mar 27;20(1):61. doi: 10.1186/s12931-019-1025-y.

9.

NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma.

Uddin M, Watz H, Malmgren A, Pedersen F.

Front Immunol. 2019 Feb 5;10:47. doi: 10.3389/fimmu.2019.00047. eCollection 2019. Review.

10.

Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study.

von Siemens SM, Jörres RA, Behr J, Alter P, Lutter J, Lucke T, Söhler S, Welte T, Watz H, Vogelmeier CF, Trudzinski F, Rief W, Herbig B, Kahnert K; COSYCONET study group.

Respir Res. 2019 Feb 11;20(1):30. doi: 10.1186/s12931-019-0997-y.

11.

On Trapped Air and Trapped Blood in Chronic Obstructive Pulmonary Disease.

Watz H.

Am J Respir Crit Care Med. 2019 May 1;199(9):1047-1048. doi: 10.1164/rccm.201901-0061ED. No abstract available.

12.

Rating sputum cell quality in clinical trials for asthma and COPD treatment.

Pedersen F, Zissler UM, Watz H, Rabe KF, Hohlfeld JM, Holz O.

Int J Chron Obstruct Pulmon Dis. 2019 Jan 8;14:195-198. doi: 10.2147/COPD.S188033. eCollection 2019. No abstract available.

13.

Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis.

Fermont JM, Masconi KL, Jensen MT, Ferrari R, Di Lorenzo VAP, Marott JM, Schuetz P, Watz H, Waschki B, Müllerova H, Polkey MI, Wilkinson IB, Wood AM.

Thorax. 2019 May;74(5):439-446. doi: 10.1136/thoraxjnl-2018-211855. Epub 2019 Jan 7.

14.

[The stepwise approach of COPD therapy].

Watz H, Kirsten A, Greulich T.

Dtsch Med Wochenschr. 2019 Jan;144(1):15-20. doi: 10.1055/a-0570-3595. Epub 2019 Jan 2. German.

PMID:
30602182
15.

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.

Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, Vogelmeier C, Calverley PMA.

Respir Res. 2018 Dec 13;19(1):251. doi: 10.1186/s12931-018-0944-3.

16.

Correction to: The all age asthma cohort (ALLIANCE) - from early beginnings to chronic disease: a longitudinal cohort study.

Fuchs O, Bahmer T, Weckmann M, Dittrich AM, Schaub B, Rösler B, Happle C, Brinkmann F, Ricklefs I, König IR, Watz H, Rabe KF, Kopp MV, Hansen G, von Mutius E; ALLIANCE Study Group as part of the German Centre for Lung Research (DZL).

BMC Pulm Med. 2018 Nov 7;18(1):165. doi: 10.1186/s12890-018-0717-2.

17.

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort.

Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.

18.

Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.

Rabe KF, Watz H, Baraldo S, Pedersen F, Biondini D, Bagul N, Hanauer G, Göhring UM, Purkayastha D, Román J, Alagappan VKT, Saetta M.

Lancet Respir Med. 2018 Nov;6(11):827-836. doi: 10.1016/S2213-2600(18)30331-X. Epub 2018 Sep 14. Erratum in: Lancet Respir Med. 2018 Oct 12;:.

PMID:
30224319
19.

Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.

Lazaar AL, Miller BE, Tabberer M, Yonchuk J, Leidy N, Ambery C, Bloomer J, Watz H, Tal-Singer R.

Eur Respir J. 2018 Oct 4;52(4). pii: 1801020. doi: 10.1183/13993003.01020-2018. Print 2018 Oct. No abstract available.

PMID:
30139779
20.

The all age asthma cohort (ALLIANCE) - from early beginnings to chronic disease: a longitudinal cohort study.

Fuchs O, Bahmer T, Weckmann M, Dittrich AM, Schaub B, Rösler B, Happle C, Brinkmann F, Ricklefs I, König IR, Watz H, Rabe KF, Kopp MV, Hansen G, von Mutius E; ALLIANCE Study Group as part of the German Centre for Lung Research (DZL).

BMC Pulm Med. 2018 Aug 20;18(1):140. doi: 10.1186/s12890-018-0705-6. Erratum in: BMC Pulm Med. 2018 Nov 7;18(1):165.

21.

Identification of novel target genes in human lung tissue involved in chronic obstructive pulmonary disease.

Heinbockel L, Marwitz S, Schromm AB, Watz H, Kugler C, Ammerpohl O, Schnepf K, Rabe KF, Droemann D, Goldmann T.

Int J Chron Obstruct Pulmon Dis. 2018 Jul 26;13:2255-2259. doi: 10.2147/COPD.S161958. eCollection 2018.

22.

Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis.

Goldmann T, Zissel G, Watz H, Drömann D, Reck M, Kugler C, Rabe KF, Marwitz S.

Respir Res. 2018 Jul 24;19(1):138. doi: 10.1186/s12931-018-0841-9.

23.

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach.

Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.

24.
25.

Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans.

Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA.

Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.

26.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
27.

A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.

Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H.

Respir Res. 2018 Apr 4;19(1):55. doi: 10.1186/s12931-018-0751-x.

28.

Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling.

Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.

PMID:
29605197
29.

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD.

Watz H, Bagul N, Rabe KF, Rennard S, Alagappan VK, Román J, Facius A, Calverley PM.

Int J Chron Obstruct Pulmon Dis. 2018 Mar 6;13:813-822. doi: 10.2147/COPD.S154012. eCollection 2018.

30.

[Guideline for the Diagnosis and Treatment of COPD Patients - Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology].

Vogelmeier C, Buhl R, Burghuber O, Criée CP, Ewig S, Godnic-Cvar J, Hartl S, Herth F, Kardos P, Kenn K, Nowak D, Rabe KF, Studnicka M, Watz H, Welte T, Windisch W, Worth H; unter Mitwirkung der folgenden wissenschaftlichen Fachgesellschaften: Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin e.V. ; Deutsche Gesellschaft für Rehabilitationswissenschaften e.V.

Pneumologie. 2018 Apr;72(4):253-308. doi: 10.1055/s-0043-125031. Epub 2018 Mar 9. German.

PMID:
29523017
31.

Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils.

Pedersen F, Waschki B, Marwitz S, Goldmann T, Kirsten A, Malmgren A, Rabe KF, Uddin M, Watz H.

Eur Respir J. 2018 Apr 12;51(4). pii: 1700970. doi: 10.1183/13993003.00970-2017. Print 2018 Apr. No abstract available.

PMID:
29449427
32.

Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD.

Graf J, Lucke T, Herrera R, Watz H, Holle R, Vogelmeier C, Ficker JH, Jörres RA.

Pulm Pharmacol Ther. 2018 Apr;49:123-129. doi: 10.1016/j.pupt.2018.01.011. Epub 2018 Feb 5.

PMID:
29421666
33.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

34.

Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.

Smid DE, Franssen FME, Gonik M, Miravitlles M, Casanova C, Cosio BG, de Lucas-Ramos P, Marin JM, Martinez C, Mir I, Soriano JB, de Torres JP, Agusti A, Atalay NB, Billington J, Boutou AK, Brighenti-Zogg S, Chaplin E, Coster S, Dodd JW, Dürr S, Fernandez-Villar A, Groenen MTJ, Guimarães M, Hejduk K, Higgins V, Hopkinson NS, Horita N, Houben-Wilke S, Janssen DJA, Jehn M, Joerres R, Karch A, Kelly JL, Kim YI, Kimura H, Koblizek V, Kocks JH, Kon SSC, Kwon N, Ladeira I, Lee SD, Leuppi JD, Locantore N, Lopez-Campos JL, D-C Man W, Maricic L, Mendoza L, Miedinger D, Mihaltan F, Minami S, van der Molen T, Murrells TJ, Nakken N, Nishijima Y, Norman IJ, Novotna B, O'Donnell DE, Ogata Y, Pereira ED, Piercy J, Price D, Pothirat C, Raghavan N, Ringbaek T, Sajkov D, Sigari N, Singh S, Small M, da Silva GF, Tanner RJ, Tsiligianni IG, Tulek B, Tzanakis N, Vanfleteren LEGW, Watz H, Webb KA, Wouters EFM, Xie GG, Yoshikawa M, Spruit MA.

J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24. doi: 10.1016/j.jamda.2017.09.003. Review.

35.

Physical Activity and Fatigue in Patients with Sarcoidosis.

Bahmer T, Watz H, Develaska M, Waschki B, Rabe KF, Magnussen H, Kirsten D, Kirsten AM.

Respiration. 2018;95(1):18-26. doi: 10.1159/000481827. Epub 2017 Nov 9.

36.

Next generation of anti-inflammatory therapy for COPD?

Watz H.

Eur Respir J. 2017 Oct 26;50(4). pii: 1702084. doi: 10.1183/13993003.02084-2017. Print 2017 Oct. No abstract available.

37.

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.

Koch A, Watz H, Maleki-Yazdi MR, Bothner U, Tetzlaff K, Voß F, McGarvey L.

NPJ Prim Care Respir Med. 2017 Oct 23;27(1):60. doi: 10.1038/s41533-017-0059-1.

38.

Lipidomes of lung cancer and tumour-free lung tissues reveal distinct molecular signatures for cancer differentiation, age, inflammation, and pulmonary emphysema.

Eggers LF, Müller J, Marella C, Scholz V, Watz H, Kugler C, Rabe KF, Goldmann T, Schwudke D.

Sci Rep. 2017 Sep 11;7(1):11087. doi: 10.1038/s41598-017-11339-1.

39.

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.

Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 24;12:2545-2558. doi: 10.2147/COPD.S143488. eCollection 2017.

40.

Brain Activation during Perception and Anticipation of Dyspnea in Chronic Obstructive Pulmonary Disease.

Esser RW, Stoeckel MC, Kirsten A, Watz H, Taube K, Lehmann K, Magnussen H, Büchel C, von Leupoldt A.

Front Physiol. 2017 Aug 23;8:617. doi: 10.3389/fphys.2017.00617. eCollection 2017.

41.

Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.

Cahn A, Hamblin JN, Begg M, Wilson R, Dunsire L, Sriskantharajah S, Montembault M, Leemereise CN, Galinanes-Garcia L, Watz H, Kirsten AM, Fuhr R, Hessel EM.

Pulm Pharmacol Ther. 2017 Oct;46:69-77. doi: 10.1016/j.pupt.2017.08.008. Epub 2017 Aug 17.

42.

Physical activity patterns and clusters in 1001 patients with COPD.

Mesquita R, Spina G, Pitta F, Donaire-Gonzalez D, Deering BM, Patel MS, Mitchell KE, Alison J, van Gestel AJ, Zogg S, Gagnon P, Abascal-Bolado B, Vagaggini B, Garcia-Aymerich J, Jenkins SC, Romme EA, Kon SS, Albert PS, Waschki B, Shrikrishna D, Singh SJ, Hopkinson NS, Miedinger D, Benzo RP, Maltais F, Paggiaro P, McKeough ZJ, Polkey MI, Hill K, Man WD, Clarenbach CF, Hernandes NA, Savi D, Wootton S, Furlanetto KC, Cindy Ng LW, Vaes AW, Jenkins C, Eastwood PR, Jarreta D, Kirsten A, Brooks D, Hillman DR, Sant'Anna T, Meijer K, Dürr S, Rutten EP, Kohler M, Probst VS, Tal-Singer R, Gil EG, den Brinker AC, Leuppi JD, Calverley PM, Smeenk FW, Costello RW, Gramm M, Goldstein R, Groenen MT, Magnussen H, Wouters EF, ZuWallack RL, Amft O, Watz H, Spruit MA.

Chron Respir Dis. 2017 Aug;14(3):256-269. doi: 10.1177/1479972316687207. Epub 2017 Feb 24.

43.

Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.

Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H.

BMC Pulm Med. 2017 Jul 25;17(1):104. doi: 10.1186/s12890-017-0444-0.

44.

Aclidinium bromide improves symptoms and sleep quality in COPD: a pilot study.

Magnussen H, Arzt M, Andreas S, Plate T, Ribera A, Seoane B, Watz H, Kirsten AM.

Eur Respir J. 2017 Jun 22;49(6). pii: 1700485. doi: 10.1183/13993003.00485-2017. Print 2017 Jun. No abstract available.

45.

Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.

Watz H, Uddin M, Pedersen F, Kirsten A, Goldmann T, Stellmacher F, Groth E, Larsson B, Böttcher G, Malmgren A, Kraan M, Rabe KF.

Pulm Pharmacol Ther. 2017 Aug;45:121-123. doi: 10.1016/j.pupt.2017.05.012. Epub 2017 May 23. No abstract available.

PMID:
28549850
46.

Chronic obstructive pulmonary disease.

Rabe KF, Watz H.

Lancet. 2017 May 13;389(10082):1931-1940. doi: 10.1016/S0140-6736(17)31222-9. Epub 2017 May 11. Review.

PMID:
28513453
47.

[Exacerbation of COPD].

Lorenz J, Bals R, Dreher M, Jany B, Koczulla R, Pfeifer M, Randerath W, Steinkamp G, Taube C, Watz H, Windisch W.

Pneumologie. 2017 May;71(5):269-289. doi: 10.1055/s-0043-106559. Epub 2017 May 15. German.

PMID:
28505687
48.

Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort.

Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, Watz H, Alter P, Fähndrich S, Bals R, Holle R, Karrasch S, Söhler S, Wacker M, Ficker JH, Parhofer KG, Vogelmeier C, Jörres RA; COSYCONET consortium.

PLoS One. 2017 May 15;12(5):e0177501. doi: 10.1371/journal.pone.0177501. eCollection 2017.

49.

Chronic obstructive pulmonary disease: inhale deeply and start to exercise.

Watz H.

Eur Respir J. 2017 Apr 19;49(4). pii: 1700424. doi: 10.1183/13993003.00424-2017. Print 2017 Apr. No abstract available.

50.

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.

Waschki B, Watz H, Holz O, Magnussen H, Olejnicka B, Welte T, Rabe KF, Janciauskiene S.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 22;12:981-987. doi: 10.2147/COPD.S128689. eCollection 2017.

Supplemental Content

Support Center